Crystals And IP April 2011

•Descargar como PPS, PDF•

1 recomendación•364 vistas

L

Linda_Mccausland

Some of the most important subject matters in Pharmaceutical IP are also the key solutions in pharmaceutical development.

Crystals and IP Linda McCausland Head of Physical Sciences April 2011

Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Issues or Advantages? Purity Yield Crystal size Solids handling Solubility Polymorphism Crystal shape Scale-up Solvates & Hydrates Isolation Dissolution

Protecting Invention ,[object Object],[object Object]

IP services ,[object Object],[object Object]

IP services continued… ,[object Object],[object Object],[object Object],[object Object]

About us ,[object Object]

Experience ,[object Object]

Technical consultancy & support ,[object Object]

Más contenido relacionado

Destacado

Rapidd™

Almac Protein Ligation Technology Webinar Presentation 12 09-2012

Almac Protein Ligation Technology Webinar Presentation 12 09-2012

Almac Protein Ligation Technology Webinar Presentation 12 09-2012

Dr.V.chandrasekharan

Dr.V.chandrasekharan

Dr.V.chandrasekharan

Solid State Capabilities

Solid State Capabilities

Solid State Capabilities

Polymorphism: opportunity or problem?

Polymorphism: opportunity or problem?

Polymorphism: opportunity or problem?

Cryst Dev Case Study Dec 2011

Cryst Dev Case Study Dec 2011

Cryst Dev Case Study Dec 2011

Linda_Mccausland

Polymorphism and crystallisation : The mysterious phenomenon

Polymorphism and crystallisation : The mysterious phenomenon

Polymorphism and crystallisation : The mysterious phenomenon

Madhulika Harde

4016 solid state analysis

4016 solid state analysis

4016 solid state analysis

NYSAS Solid State Spectroscopy Of Materials (Polymorphism)

NYSAS Solid State Spectroscopy Of Materials (Polymorphism)

NYSAS Solid State Spectroscopy Of Materials (Polymorphism)

$X-ray Powder Diffraction:exposing the bare bones of solid forms$ $X-ray Powder Diffraction:exposing the bare bones of solid forms$

X-ray Powder Diffraction:exposing the bare bones of solid forms

Linda_Mccausland

Polymorph Quantitation

Polymorph Quantitation

Polymorph Quantitation

Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...

Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...

Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...

Pharmaceutical Solid Form

Pharmaceutical Solid Form

Pharmaceutical Solid Form

FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. A presentation compiled from material freely available on the WEB to introduce the concepts of QbD for beginners.

Quality by Design

Quality by Design

Quality by Design

GMP EDUCATION : Not for Profit Organization

Seminar on polymorphism

Seminar on polymorphism

Seminar on polymorphism

Polymorphism

Destacado (16)

Rapidd™

Almac Protein Ligation Technology Webinar Presentation 12 09-2012

Almac Protein Ligation Technology Webinar Presentation 12 09-2012

Almac Protein Ligation Technology Webinar Presentation 12 09-2012

Dr.V.chandrasekharan

Dr.V.chandrasekharan

Dr.V.chandrasekharan

Solid State Capabilities

Solid State Capabilities

Solid State Capabilities

Polymorphism: opportunity or problem?

Polymorphism: opportunity or problem?

Polymorphism: opportunity or problem?

Cryst Dev Case Study Dec 2011

Cryst Dev Case Study Dec 2011

Cryst Dev Case Study Dec 2011

Polymorphism and crystallisation : The mysterious phenomenon

Polymorphism and crystallisation : The mysterious phenomenon

Polymorphism and crystallisation : The mysterious phenomenon

4016 solid state analysis

4016 solid state analysis

4016 solid state analysis

NYSAS Solid State Spectroscopy Of Materials (Polymorphism)

NYSAS Solid State Spectroscopy Of Materials (Polymorphism)

NYSAS Solid State Spectroscopy Of Materials (Polymorphism)

$X-ray Powder Diffraction:exposing the bare bones of solid forms$ $X-ray Powder Diffraction:exposing the bare bones of solid forms$

X-ray Powder Diffraction:exposing the bare bones of solid forms

Polymorph Quantitation

Polymorph Quantitation

Polymorph Quantitation

Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...

Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...

Almac - The Manufacture of Peptides for Clinical Trials - 2nd Irish Peptide S...

Pharmaceutical Solid Form

Pharmaceutical Solid Form

Pharmaceutical Solid Form

Quality by Design

Quality by Design

Quality by Design

Seminar on polymorphism

Seminar on polymorphism

Seminar on polymorphism

Polymorphism

Similar a Crystals And IP April 2011

Origiin Corporate Presentation 01

Origiin Corporate Presentation 01

Origiin Corporate Presentation 01

Competitive landsape by Clarivate Analytics

Competitive landsape by Clarivate Analytics

Competitive landsape by Clarivate Analytics

Kemxtree Presentation

Kemxtree Presentation

Kemxtree Presentation

Alyante is a custom research services organisation that delivers quality research to help improve your research efficiencies. It provides comprehensive end-to-end solutions ranging from chemical and pharmaceutical development to product supply, including complete regulatory support for filing. To enhance your product portfolio, Alyante offers innovative services including NDDS. Alyante’s array of innovation-based services and commitment to excellence will help you create new value. Alyante is an assurance of an alliance that strives to keep your research always ahead of the competition through innovation and trust.

Alyante Introduction Presentation

Alyante Introduction Presentation

Alyante Introduction Presentation

Wockhardt Limited

Dnal 1

Importance Of Patents In The Life Sciences Industry

Importance Of Patents In The Life Sciences Industry

Importance Of Patents In The Life Sciences Industry

Report’s Key Features • PDF with > 140 slides • Excel file > 2,450 patent families • IP trends, including time-evolution of published patents, and countries of patent filings • Patents’ legal status • Ranking of main patent assignees • Key players’ IP position and relative strength of their patent portfolios • Summary of the IP related to applications: Cancer therapy, Cosmetic, Diabetes, Ophthalmic, Pain management and Vaccine. • Summary of the IP related to technologies: Applicators, housing, Coated, Hollow, Porous, Soluble, Hydrogel and Solid microneedles. • Analysis of patent oppositions (Europe) and review of key patents. • Excel database containing all patents analyzed in the report, including applications and technologies segmentations

Microneedles for drug delivery patent landscape 2020 flyer

Microneedles for drug delivery patent landscape 2020 flyer

Microneedles for drug delivery patent landscape 2020 flyer

Short introduction to Imperial Innovations

Short introduction to Imperial Innovations

Short introduction to Imperial Innovations

Food Nutraceutical Packaging Chemistry Presentation

Food Nutraceutical Packaging Chemistry Presentation

Food Nutraceutical Packaging Chemistry Presentation

Health and life sciences Webinar 25th September 2013

Health and life sciences Webinar 25th September 2013

Health and life sciences Webinar 25th September 2013

CambridgeIP Ltd

Methods to improve Freedom to Operate analysis

Methods to improve Freedom to Operate analysis

Methods to improve Freedom to Operate analysis

Polymorph patents

Polymorph patents

Polymorph patents

IPR Collateral 4bridge

IPR Collateral 4bridge

IPR Collateral 4bridge

FourBridgeTechnologies

Capsule Endoscopy Patent Landscape 2014 Sample Olympus and Given Imaging are leading intellectual property in the capsule endoscopy industry, but for how long? KEY FEATURES OF THE REPORT The report provides essential patent data for capsule endoscopy. It identifies more than 30 major holders of capsule endoscopy related intellectual property. It provides in-depth IP analysis and industrial key players including: -Time evolution of patent publications and countries of patent filings. -Current legal status of patents. -Ranking of main patent applicants. -Joint developments and IP collaboration network of main patent applicants. -Key patents. -Granted patents near expiration. -Relative strength of main companies IP portfolio. -Overview of patent litigations. -Matrix applicants/technology issues for more than 15+ companies. The “capsule endoscopy IP” profiles of 15+ major companies is presented, with key patents, technological issues, litigations, licenses, partnerships, and IP strength and strategy. The report also provides an extensive Excel database with all patents analyzed in the report. OBJECTIVE OF THE REPORT •Understand the IP landscape for capsule endoscopy. •Identify key patents. •Understand trends in capsule endoscopy IP. •Identify the major players in capsule endoscopy IP and the relative strength of their patent portfolio. •Identify new players in capsule endoscopy IP. •Identify IP collaboration networks between key players (industrial and academics). •Identify main patent litigations.

Capsule endoscopy Patent Landscape 2014 Sample

Capsule endoscopy Patent Landscape 2014 Sample

Capsule endoscopy Patent Landscape 2014 Sample

Photoacoustic imaging technologies in the biomedical domain are in full growth from an IP point of view, and have began to move in the clinical field. If Japanese companies Canon and Fujifilm are the main IP holder, the market is held by US actors : ENDRA Life Sciences, VisualSonics, Seno Medical Instruments, OptoSonics or TomoWave Laboratories. This patent landscape focuses on photoacoustic imaging in biomedicine. Photoacoustic imaging is a safe, non-invasive, non-ionizing imaging technique. The technique offers several advantages and represents a great alternative to traditional medical imaging approaches. The innovation of photoacoustic imaging for biomedical purposes is mainly driven by the need to enhance the efficiency of the detection and diagnostic of cancer. KEY FEATURES OF THE REPORT The report provides essential patent data for biomedical photoacoustic imaging including: Time evolution of patent publications and countries of patent filings. Current legal status of patents. Ranking of main patent applicants. Joint developments and IP collaboration network of main patent applicants. Key patents. Granted patents near expiration. Relative strength of main companies IP portfolio. Photoacoustic imaging IP profiles of 15 major companies with key patents, partnerships, and IP strength and strategy. The report also provides an extensive Excel database with all patents analyzed in the study.

Biomedical Photoacoustic Imaging Patent Landscape Sample

Biomedical Photoacoustic Imaging Patent Landscape Sample

Biomedical Photoacoustic Imaging Patent Landscape Sample

ENSafrica Pharma - Biotech IP Capability Statement 2016

ENSafrica Pharma - Biotech IP Capability Statement 2016

ENSafrica Pharma - Biotech IP Capability Statement 2016

Joanne van Harmelen

Workshop 2 - Legal Concerns (Steve Davey) Cullens Brochure

Workshop 2 - Legal Concerns (Steve Davey) Cullens Brochure

Workshop 2 - Legal Concerns (Steve Davey) Cullens Brochure

Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.

Nutriband Inc. 2021 Deck

Nutriband Inc. 2021 Deck

Nutriband Inc. 2021 Deck

RedChip Companies, Inc.

Overcoming Organizational Barriers

Overcoming Organizational Barriers

Overcoming Organizational Barriers

What is patent monetization and how does it differ from a typical licensing deal? The process of due diligence for patent monetization - how do you choose patents which would be great candidates for monetization? What are some of the intangibles at institutions that prevent patent monetization? How do you convince your institution about patent monetization? The business model for patent monetization? Who pays for it? What's in it for me? What do net revenues vs gross revenue really mean in the context of monetization? Legal considerations for patent monetization. What are some of the risks? How long does it take? How do the recent policy changes and case law impact patent monetization? Is patent monetization ethical? These and many more topics will be covered in great detail with an opportunity to ask questions to the panelists who are world-leading experts in business, legal, and policy matters.

What to know if it is your first rodeo in patent monetization.pptx

What to know if it is your first rodeo in patent monetization.pptx

What to know if it is your first rodeo in patent monetization.pptx

Similar a Crystals And IP April 2011 (20)

Origiin Corporate Presentation 01

Origiin Corporate Presentation 01

Origiin Corporate Presentation 01

Competitive landsape by Clarivate Analytics

Competitive landsape by Clarivate Analytics

Competitive landsape by Clarivate Analytics

Kemxtree Presentation

Kemxtree Presentation

Kemxtree Presentation

Alyante Introduction Presentation

Alyante Introduction Presentation

Alyante Introduction Presentation

Dnal 1

Importance Of Patents In The Life Sciences Industry

Importance Of Patents In The Life Sciences Industry

Importance Of Patents In The Life Sciences Industry

Microneedles for drug delivery patent landscape 2020 flyer

Microneedles for drug delivery patent landscape 2020 flyer

Microneedles for drug delivery patent landscape 2020 flyer

Short introduction to Imperial Innovations

Short introduction to Imperial Innovations

Short introduction to Imperial Innovations

Food Nutraceutical Packaging Chemistry Presentation

Food Nutraceutical Packaging Chemistry Presentation

Food Nutraceutical Packaging Chemistry Presentation

Health and life sciences Webinar 25th September 2013

Health and life sciences Webinar 25th September 2013

Health and life sciences Webinar 25th September 2013

Methods to improve Freedom to Operate analysis

Methods to improve Freedom to Operate analysis

Methods to improve Freedom to Operate analysis

Polymorph patents

Polymorph patents

Polymorph patents

IPR Collateral 4bridge

IPR Collateral 4bridge

IPR Collateral 4bridge

Capsule endoscopy Patent Landscape 2014 Sample

Capsule endoscopy Patent Landscape 2014 Sample

Capsule endoscopy Patent Landscape 2014 Sample

Biomedical Photoacoustic Imaging Patent Landscape Sample

Biomedical Photoacoustic Imaging Patent Landscape Sample

Biomedical Photoacoustic Imaging Patent Landscape Sample

ENSafrica Pharma - Biotech IP Capability Statement 2016

ENSafrica Pharma - Biotech IP Capability Statement 2016

ENSafrica Pharma - Biotech IP Capability Statement 2016

Workshop 2 - Legal Concerns (Steve Davey) Cullens Brochure

Workshop 2 - Legal Concerns (Steve Davey) Cullens Brochure

Workshop 2 - Legal Concerns (Steve Davey) Cullens Brochure

Nutriband Inc. 2021 Deck

Nutriband Inc. 2021 Deck

Nutriband Inc. 2021 Deck

Overcoming Organizational Barriers

Overcoming Organizational Barriers

Overcoming Organizational Barriers

What to know if it is your first rodeo in patent monetization.pptx

What to know if it is your first rodeo in patent monetization.pptx

What to know if it is your first rodeo in patent monetization.pptx

Crystals And IP April 2011

1. Crystals and IP Linda McCausland Head of Physical Sciences April 2011

2.

3. Issues or Advantages? Purity Yield Crystal size Solids handling Solubility Polymorphism Crystal shape Scale-up Solvates & Hydrates Isolation Dissolution

4.

5.

6.

7.

8.

9.